Billing chart: Blue Cross highlights medical, benefit policy changes

July 10, 2023

Policies with Updates:

Evaluation of biomarkers for Alzheimer’s
Genetic testing: Analysis of MGMT in malignant gliomas
Pharmacogenomic and metabolite markers for treatment with thiopurines
JAK2, MPL and CALR genetic testing for myeloproliferative neoplasms

Source: https://www.bcbsm.com/content/dam/microsites/corpcomm/provider/the_record/2023/jul/Record_0723d.html

Sign up for Billing Beat